{"id":690668,"date":"2022-09-30T08:16:02","date_gmt":"2022-09-30T12:16:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scpharmaceuticals-announces-data-presentations-at-the-heart-failure-society-of-america-2022-annual-scientific-meeting\/"},"modified":"2022-09-30T08:16:02","modified_gmt":"2022-09-30T12:16:02","slug":"scpharmaceuticals-announces-data-presentations-at-the-heart-failure-society-of-america-2022-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scpharmaceuticals-announces-data-presentations-at-the-heart-failure-society-of-america-2022-annual-scientific-meeting\/","title":{"rendered":"scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting"},"content":{"rendered":"

\nPresentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX\u00ae (furosemide injection) at home
\n<\/h2>\n
\n

BURLINGTON, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced two poster presentations, including a late breaker, at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, which is being held September 30 \u2013 October 3, in Washington DC.<\/p>\n

\u201cWe are very pleased to have an opportunity to present scientific data at this year\u2019s HFSA Annual Scientific Meeting, which is among the most important and well attended gatherings of heart failure experts each year,\u201d stated John Tucker, chief executive officer of scPharmaceuticals. \u201cThe two presentations highlight the significant potential benefits \u2013 both to patients and payers \u2013 of an alternative approach to the management of congestion in patients with heart failure outside of the hospital. We believe FUROSCIX (furosemide injection), if approved, represents a potential new model for the treatment of congestion in patients with heart failure by allowing IV-equivalent diuresis at home, thus potentially reducing costly hospital admissions and readmissions.\u201d<\/p>\n

\u201cWe are eagerly approaching our October 8 FUROSCIX PDUFA target action date, and, assuming FDA approval, are well prepared to initiate a robust commercial launch of FUROSCIX in 2022,\u201d Mr. Tucker concluded.<\/p>\n

\n Details of the presentations are as follows:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n
\n Title: <\/strong>\n <\/td>\n\n Avoiding Treatment in Hospital with FUROSCIX to Manage Congestion in Heart Failure (AT HOME-HF) \u2013 A Pilot Study<\/strong>\n <\/td>\n<\/tr>\n
\n Poster #:<\/strong>\n <\/td>\nLBA-007 (late breaking)<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nGeneral Poster Viewing Session II<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nSaturday, October 1, 2022<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n12:45pm \u2013 1:00pm EDT<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nExhibit Hall ePoster Hub<\/td>\n<\/tr>\n
\n Summary:<\/strong>\n <\/td>\nThis poster describes the results of a Phase 2, multicenter, pilot study where 51 subjects presenting to a heart failure clinic with worsening congestion requiring augmented diuresis were randomized (2:1) to receive FUROSCIX or enhanced oral diuretics.<\/td>\n<\/tr>\n<\/table>\n

\n

Subjects who received FUROSCIX demonstrated augmented decongestion compared with patients receiving enhanced oral diuretics as demonstrated by:<\/p>\n